BRPI0921407A2 - terapia de combinação seletiva de erbb-3 (her3) - Google Patents
terapia de combinação seletiva de erbb-3 (her3)Info
- Publication number
- BRPI0921407A2 BRPI0921407A2 BRPI0921407A BRPI0921407A BRPI0921407A2 BR PI0921407 A2 BRPI0921407 A2 BR PI0921407A2 BR PI0921407 A BRPI0921407 A BR PI0921407A BR PI0921407 A BRPI0921407 A BR PI0921407A BR PI0921407 A2 BRPI0921407 A2 BR PI0921407A2
- Authority
- BR
- Brazil
- Prior art keywords
- her3
- erbb
- combination therapy
- selective combination
- selective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11254908P | 2008-11-07 | 2008-11-07 | |
| PCT/US2009/063357 WO2010054051A1 (en) | 2008-11-07 | 2009-11-05 | Erbb-3 (her3)-selective combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0921407A2 true BRPI0921407A2 (pt) | 2019-09-24 |
Family
ID=42153234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0921407A BRPI0921407A2 (pt) | 2008-11-07 | 2009-11-05 | terapia de combinação seletiva de erbb-3 (her3) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120004285A1 (pt) |
| EP (1) | EP2376087A4 (pt) |
| JP (1) | JP2012508244A (pt) |
| KR (1) | KR20110086844A (pt) |
| CN (1) | CN102223886A (pt) |
| AU (1) | AU2009313510A1 (pt) |
| BR (1) | BRPI0921407A2 (pt) |
| CA (1) | CA2741050A1 (pt) |
| EA (1) | EA201170660A1 (pt) |
| IL (1) | IL212714A0 (pt) |
| MX (1) | MX2011004869A (pt) |
| NZ (1) | NZ592326A (pt) |
| TW (1) | TW201021803A (pt) |
| WO (1) | WO2010054051A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006084058A2 (en) | 2005-02-03 | 2006-08-10 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
| WO2007056118A1 (en) | 2005-11-04 | 2007-05-18 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| EP2915532B1 (en) | 2008-06-17 | 2016-10-19 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
| ES2614912T3 (es) | 2008-08-04 | 2017-06-02 | Wyeth Llc | Combinaciones antineoplásicas de 4-anilino-3-cianoquinolinas y capecitabina |
| EP3000467B1 (en) | 2009-04-06 | 2023-03-01 | Wyeth LLC | Treatment regimen utilizing neratinib for breast cancer |
| CN104093743B (zh) | 2011-11-23 | 2018-04-24 | 医学免疫有限责任公司 | 特异于her3的结合分子及其用途 |
| WO2015048008A2 (en) | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
| WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
| US11214774B2 (en) * | 2015-05-01 | 2022-01-04 | Andrew Man Chung Wo | PINK1 C-terminal domain polypeptide and methods using the same in cancer treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050176024A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA) |
| US6919340B2 (en) * | 2002-04-19 | 2005-07-19 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
| WO2004070062A2 (en) * | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
| WO2007031091A2 (en) * | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| US20100112687A1 (en) * | 2007-03-02 | 2010-05-06 | Mdrna, Inc. | Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof |
| US20080287383A1 (en) * | 2007-03-02 | 2008-11-20 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting erbb gene expression and uses thereof |
| EP2155877A2 (en) * | 2007-05-11 | 2010-02-24 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of her3 |
-
2009
- 2009-11-05 KR KR1020117013001A patent/KR20110086844A/ko not_active Application Discontinuation
- 2009-11-05 EA EA201170660A patent/EA201170660A1/ru unknown
- 2009-11-05 EP EP09825396.6A patent/EP2376087A4/en not_active Withdrawn
- 2009-11-05 MX MX2011004869A patent/MX2011004869A/es not_active Application Discontinuation
- 2009-11-05 JP JP2011535663A patent/JP2012508244A/ja not_active Withdrawn
- 2009-11-05 CA CA2741050A patent/CA2741050A1/en not_active Abandoned
- 2009-11-05 BR BRPI0921407A patent/BRPI0921407A2/pt not_active IP Right Cessation
- 2009-11-05 WO PCT/US2009/063357 patent/WO2010054051A1/en active Application Filing
- 2009-11-05 NZ NZ592326A patent/NZ592326A/xx not_active IP Right Cessation
- 2009-11-05 CN CN2009801447096A patent/CN102223886A/zh active Pending
- 2009-11-05 US US13/127,270 patent/US20120004285A1/en not_active Abandoned
- 2009-11-05 AU AU2009313510A patent/AU2009313510A1/en not_active Abandoned
- 2009-11-06 TW TW098137735A patent/TW201021803A/zh unknown
-
2011
- 2011-05-05 IL IL212714A patent/IL212714A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20120004285A1 (en) | 2012-01-05 |
| AU2009313510A1 (en) | 2010-05-14 |
| MX2011004869A (es) | 2011-06-20 |
| EP2376087A1 (en) | 2011-10-19 |
| IL212714A0 (en) | 2011-07-31 |
| EP2376087A4 (en) | 2013-06-05 |
| KR20110086844A (ko) | 2011-08-01 |
| JP2012508244A (ja) | 2012-04-05 |
| EA201170660A1 (ru) | 2011-12-30 |
| TW201021803A (en) | 2010-06-16 |
| CA2741050A1 (en) | 2010-05-14 |
| CN102223886A (zh) | 2011-10-19 |
| WO2010054051A1 (en) | 2010-05-14 |
| NZ592326A (en) | 2013-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2018006I1 (lt) | Pakeistųjų oksazolidinonų kombinuota terapija | |
| BRPI0921407A2 (pt) | terapia de combinação seletiva de erbb-3 (her3) | |
| BRPI0910854A2 (pt) | métodos de tratamento | |
| BRPI0921327A2 (pt) | Combinação de herbicida-protetor | |
| BR112012005594A2 (pt) | tratamento de câncer | |
| DE602009000539D1 (de) | Strahlentherapiegerät | |
| BRPI0818380A2 (pt) | Combinação de herbicida-protetor | |
| BRPI0907457A2 (pt) | Absorventes | |
| BRPI0916931A2 (pt) | agentes terapêuticos | |
| BRPI0913832A2 (pt) | derivados de pirrolopiridinilpirimidin-2-ilamina | |
| BRPI0915064A2 (pt) | derivados de qunoxalinadiona | |
| BRPI0919748A2 (pt) | dipositivo de tratamento | |
| DK2133652T3 (da) | Minerydningsanordning | |
| DK2837348T3 (da) | Kryokirurgiske fremgangsmåder | |
| BRPI0910534A2 (pt) | terapia antiviral | |
| DK2173831T3 (da) | Brøndbehandling | |
| BRPI0913234A2 (pt) | derivados de tiazolilpiperidina | |
| DK3150178T3 (da) | Stimuleringsapparat | |
| BRPI0820410A2 (pt) | Lactans substituídos terapêuticos | |
| BRPI0922728A2 (pt) | combinação de herbicida-antídoto | |
| BRPI0922652A2 (pt) | Derivados de quinazolinamida | |
| BRPI0818598A2 (pt) | agentes terapêuticos - 802 | |
| BRPI0808029A2 (pt) | Derivados de azabicicloalcano de subtipo seletivo | |
| BRPI0917248A2 (pt) | aralquilsilano ativado contendo halogênio | |
| BRPI0811478A2 (pt) | Compostos de morphinan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |